Summary
Global Markets Direct’s, ‘Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H1 2016’, provides in depth analysis on Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted pipeline therapeutics.
The report provides comprehensive information on the Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2)
- The report reviews Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Actelion Ltd
Eisai Co., Ltd.
Evotec AG
Heptares Therapeutics Limited
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) Overview 7
Therapeutics Development 8
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Stage of Development 8
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Therapy Area 9
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Indication 10
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Companies 13
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development 19
Actelion Ltd 19
Eisai Co., Ltd. 20
Evotec AG 21
Heptares Therapeutics Limited 22
Johnson & Johnson 23
Merck & Co., Inc. 24
Novartis AG 25
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles 26
DORA-12 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
HTL-6641 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
JNJ-42847922 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
lemborexant - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
MK-8133 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecule to Inhibit OX2R for Insomnia - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Dormant Projects 38
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products 39
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Featured News & Press Releases 40
Mar 11, 2016: Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202 40
Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients 41
Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder 41
Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202 42
Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist 42
Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist 43
Feb 03, 2015: Merck’s Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 44
Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia 45
Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 46
Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan 46
Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial 47
Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia 47
Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck’s Investigational Medicine for Insomnia 49
May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose 50
May 20, 2013: Merck's Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says 50
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53
List of Tables
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Action, H1 2016 16
Number of Products by Stage and Route of Administration, H1 2016 17
Number of Products by Stage and Molecule Type, H1 2016 18
Pipeline by Actelion Ltd, H1 2016 19
Pipeline by Eisai Co., Ltd., H1 2016 20
Pipeline by Evotec AG, H1 2016 21
Pipeline by Heptares Therapeutics Limited, H1 2016 22
Pipeline by Johnson & Johnson, H1 2016 23
Pipeline by Merck & Co., Inc., H1 2016 24
Pipeline by Novartis AG, H1 2016 25
Dormant Projects, H1 2016 38
Discontinued Products, H1 2016 39
List of Figures
Number of Products under Development for, H1 2016 8
Number of Products under Development by Top 10 Indication, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Actions, H1 2016 16
Number of Products by Stage and Routes of Administration, H1 2016 17
Number of Products by Stage and Molecule Type, H1 2016 18
